• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention provides certain di-t-butylphenols, their pharmaceutical formulations, and their use in treating inflammation, stroke, and arthritis in mammals.
    公开号:SU1516012A3
    申请号:SU864027906
    申请日:1986-08-08
    公开日:1989-10-15
    发明作者:Энн Панетта Джилл
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to a process for the preparation of new chemical compounds of 5- (4-hydroxy-3,5-di-tert.butylphenyl) -methylene thiazolidinone-4 or its derivatives, which possess anti-inflammatory and anti-arthritic
    properties and can be used in medicine.
    The purpose of the invention is to obtain new 5- (4-hydroxy-3,5-di-tert.butyl-phenyl) -methylene thiazolidinones;
    cm
    new pharmacological properties in this range of compounds.
    Example 1, Preparation of 5- (3,5- -di-tert-butyl-4-hydroxyphenyl) methylene-2-thioxo-4-thiazolidinone (compound H).
    Under nitrogen in 2500 ml of glacial acetic acid, 117.2 g of 3,5-di-tert-butyl-4-hydroxybenzaldehyde, 66.6 g of rodanine and 143.5 g of fused sodium acetate are heated to boiling. After heating for 23 hours, the reaction mixture is cooled and transferred to a mixture of 1 L of ethanol and 1 L of ice water and stirred. 500 ml of water are added after stirring for 30 minutes and the precipitate formed is separated by filtration. The solid is weighed into 500 ml of ethyl acetate and filtered. The precipitate obtained is dissolved in 3 liters of ethanol, boiled and water is added until the solution becomes cloudy, about 450 ml. After cooling the mixture to room temperature by filtration, 99.6 g of the expected product are obtained, m.p. about 260 ° C.
    Calculated,%: C, 61.86; H 6.63; N 4.01.
    C ,, H, 3NOiS ,.
    Found,%: C 62.13; H 6.55; N 4.15.
    Examples 2-3. 5- (3,5-di-tert-butyl-4-hydroxyphenyl) -methylene-4-thiazolidinone (compound lib) and 5- (3,5-bis 1,1-dimethylethyl) -5- (3.5 -di-tert-butyl-4-hydroxyphenyl) metsh1-4-thiazolidinone (compound He).
    A solution of 69.9 g of 5- (3,5-di-tert.butythyl-4-hydroxyphenyl) methylan-2-thiox-4-thiazolidinone in 4 l of ethanol is hydrogenated under a pressure of 500 psi (35 atm) for 24 hours at 100 C in the presence of 200 g of 5% palladium on carbon. The reaction mixture is filtered and evaporated to dryness. The product is dissolved in portions in 1 volume of hot ethyl acetate, diluted with 2 volumes of hexane, filtered, and loaded onto a chromatographic column filled with silica gel. By washing with a solution of 35% ethyl acetate in hexane, different fractions are obtained, which are combined according to the purity of each compound. A total of 4.6 g of the compound Hb was obtained by chromatography. The fractions with the predominant content of the compound lib are crystallized from a mixture of ethyl acetate and hexane with
    0
    five
    0
    five
    0
    five
    0
    five
    emitting a total of 13.79 g of compound lib. Repeated chromatography of the fractions containing contaminated compound 11c on silica with a total of 9.82 g of compound He to elute the 25% ethyl acetate in hexane.
    2.5- (3, 5-di-tert. Butyl) -4-hydroxyphenyl methylene-4-thiazolidinone, m.p., 209-213 C.
    Calculated,%: C 67.67; H 7.89; N 4.38.
    C, gH. S.
    Found,%: C 67.44; H 8.11; N 4.65.
    3.5- (3,5-bis (1, 1-dimethylethyl) -4-hydroxyphenyl methyl) -4-thiazolidone, m.p. 149-152 C.
    Calculated,%: C, 67.25; H 8.47; N 4.36.
    C, gH5, NO, S.
    Found,%: C 67.43; H 8.44; N 4.21.
    Example 4. 5- (3,5-di-tert.butyl-4-hydroxyphenyl) methylene-3-methyl-2-thioxo-4-thiazolidinone.
    The title compound was obtained in 76% yield according to the procedure of Example 1 based on 3, butyl-4-hydroxybenzaldehyde and methylrodamine, mp. 260 ° C.
    Calculated,%: C, 62.77; H 6.93; N 3.85; S 17.64.
    C h jKOjS j.
    Found Z: C 62.54; H 7.05; N 3,66; S 17.82.
    Example 5. 5- (3,5-di-tert.butyl-4-hydroxyphenyl) methylene-3-methyl-4-thiazolidinone.
    The title compound was obtained in 71% yield by boiling for 1 h 10.31 g of the thio of Example 4 with 38.15 ml of tri-n-butyl acid hydrate and 1.16 g of azobisisobutyronitrile (AIBN) in 142 ml of toluene. The product was added by adding water to the cooled reaction mixture, separating the layers, washing the organic layer with 1N hydrochloric acid and using sodium chloride solution, drying over magnesium sulfate, concentrating in vacuo and purifying the residue by chromatography on silica gel using hexane. ht1.ch cetate with a gradient of 10-50%. The purified product has a mp. .
    %, C: 68.43; H 8.13; N 4.20.
    C ,.
    Found,%: C 68.68; H 8.00; N 3.97.
    Example 6. 5-p, 5-di-tert, butyl-4-hydroxyphenyl) methylene-3-ethyl-4-thiazolidinone.
    To a solution of 9.58 g of 5- (3,5-di-tert, butyl-4-g and i-hydroxyphenyl) methyl en-4-thiazolidinone in 150 ml of tetrahydrofuran dbbavl 1.2 g of a 60% sodium hydride dispersion in mineral oil. After the evolution of gas has ceased, a ml of ethyl iodide is added and the reaction mixture is stirred for 2 days under argon atmosphere. The mixture is boiled for 6 hours, cooled, diluted with diethyl ether and water and the addition of 1N. hydrochloric acid is adjusted to pH 3. The layers are separated, the organic layer is washed with a saturated solution of sodium bicarbonate and then with an saturated solution of sodium chloride. Concentration of the dried organic solution and chromatography of the obtained residue on silica gel using a 10–30% gradient of ethyl acetate in a hexane gives 3.65 g of the desired title product, mp. 169-1 72.5
    phospholipase inhibitors A. Moreover, the compounds showed activity in vivo in various test systems designed to detect anti-inflammatory and anti-arrhythmic agents. This pharmacodynamic effect is shown in the following test systems.
    Experiments with carrageenin. The compounds are tested for anti-inflammatory activity. In this test, inflammation was caused by injection of carrageenan into the hind paws of rats. The test compounds were injected before the injection to determine the percentage of inhibition compared to the control animals. The results obtained are shown in Table i. one .
    Table
    Calculated,%: C 69, 12; H 8, .41; N 4.03.
     CjoH NOiS.
    Found,%: C 69.39; H 8.52; N 4.30.
    Examples 7-8. According to the procedure of Example 6, using the appropriate alkyl iodide, the following compounds are prepared.
    7.5- (3,5-di-tert, butyl-4-hydroxy-phenyl) methylene-3-propyl-4-thiazolidine 60% yield, m.p. 145-146.5 ° C.
    Calculated,%: C 69,76; H 8.64; N 3.87.
    C4, H j, NOiS.
    Found,%: C 70.5; H 8.76; N 4.01.
    8.5- (3,5-di-tert. Butyl-4-hydroxyphenyl) methylene-3-butyl-4-thiazolidine, 60% yield, m.p. 168.5-169,
    Calculated Z: C 70.36; H 8.85; N 3.73.
    Cj, jHjjNO S.
    Found,%: C, 70.60; H 8.81; N 3.97.
    The study of the pharmacological activity of the compounds obtained according to the proposed method. The compounds of formula I inhibit in vitro 5-lipogenase. In addition, the compounds are ingi
    .




    0
    orally with the help of a gastric probe passed through the nose.
    Antigen-induced granuloma-like inflammation in guinea pigs.
    Guinea pigs of both sexes of a line on Harttey weighing 250-300 g were made sensitive to ovalbumin by injecting each animal with a single dose of 1 μg of ovalbumin mixed with 50 mg of aluminum hydroxide. These animals were used on days 21-26 for injection into the pads of ovalbumin covalently bound to agarose.
    Granuloma-like inflammation was injected with 0.1 ml of Affigel Ovalbumin (Bio-Rad Laboratories, Richmond, California) in the pads of the sensitive guinea pigs. Three days after the injection, the volume of injected and non-injected foot pads was measured. The volume of the legs (pads) was measured by displacing water using a Statham a pressure sensor and a digital voltmeter. The difference in paw volumes between injection-cyrillic and injected paws indicates the degree of inhibition. Histological examination of the inflamed paws showed 1 neutrophil filtration between the first and third days and macrophages by the third day. By day 11, focal extensive granuloma-like inflammation was observed. A noticeable infiltration of inflammatory cells, mainly consisting of macrophages with a smaller number of multinuclear giant cells, zoosinophils, plasma cells and lymphocytes, was surrounded by the spheres of Affigel Ovalbimine.
    :
    Groups of five guinea pigs that received an injection of Affigel ovalbumin in the paw three days before were given a test compound, clinical antirheumatic drugs, such as penicylamine or placebo, which were mixed into the diet for 8 days or were administered orally through the nose using gastric probe within 4 days. The volumes of the legs and the difference in the volumes of the injected and non-injected legs were measured with a difference on the 3rd day and the day the treatment was started with the medication. The percentage of inhibition of granulolemosis was calculated by the following test:
    raz.ob. -I :. % inhibition (1-az7ab7-3
    X 100
    where time, ob-3 is the difference in paw volumes between injected and non-injected paws on the 3rd day, time. v.-II - difference in the volumes of injected and non-injected paws on the 11th day. The results of the tests are summarized in table. 2
    Experiments with caused by collagen arthritis.
    Type II collagen was isolated from the bovine articular cartilage. Collagen was dissolved in acetic acid and stored at -20 ° C. Collagen type IT was diluted to a concentration of 2 mg / ml and was thoroughly emulsified in an equal amount of about 1, with incomplete adjuvant Freund a (NEF). Emulsion containing approximately 0.5 mg of collagen was injected in groups of 6 inbred rats. Lewis (suppliers of Charles Rwir, males for 170-200 g) to various places of the back. The injection was administered on the day O intradermally. Three times a week during the test
    .Q
    15
    20
    -
    thirty
    , r d
    and fixed hind paw volumes to detect the inflammatory response. Starting from the 1st day of the test, the group of animals received the compounds in the form of suspensions in carboxymethyl cellulose (carrier) orally via a stomach tube 5 days a week (monday). Control animals received a vehicle without the test compound. At the end of the test (day 28 or 30), blood was collected from the animals using cardiac function, in which using the method with passive gluing of red blood cells, the level of antibodies to anti-type II collagen in serum was detected using glutamine-treated cells. red aldehyde red sheep blood cells to which type II collagen is conjugated. Cell signal or supersensitive pending feedback on type II collagen was measured using a radiometric ear gauge. In some cases, radiographs of the hind legs of 2 or 3 animals from each group determined the bone damage caused by immunization with a type II co-fold and drug action. NFVW without collagen II injections were used in some rats as negative controls, such rats received only carmethoxycellulose (vehicle) during the test.
    The results of testing compounds of formula I in a system with collagen arthritis, are summarized in Table 3,% inhibition was calculated using the following formula:
    V t Vv% inhibition (1 - ------) x100
     with v
    where V is the volume of the hind paw of the animal of the treated compound (test group); V is the volume of the hind paw of the animal that did not receive the compound. (carrier-carbmethoxycellulose only, control group); - volume of the hind paw of the animal treated with the carrier (carbmethoxycellulose) and NFWV without collagen II (negative control group).
    Anti-inflammatory activity in experiments with the granuloma caused by the antigen is given in table. 2
    table 2
    Inhibition of collagen-induced arthritis is given in Table. 3 Table 3
    A test for the development of adjuvant-induced arthritis in rats,
    The compounds were tested for their ability to alter the swelling of the hindpaw and for bone damage resulting from the excipient-induced edema in rats. In order to quantify the inhibition of hind paw swelling as a result of anAnother adjuvant arthritis, a definition of two phases of inflammation has been made: (1) primary and secondary and injected hind paws and (2) secondary and non-injected hind paws, which begins to develop after about 1) days induction of inflammation in the injected foot. A decrease in the latter type of inflammation is evidence of immunosuppressive activity.
    Adjuvant-induced arthritis was induced in male dogs.
    beat Lewis-Wistar rats (200-210 g) with a single seeding injection into the right hind paw with 0.1 ml of a 0.5% suspension of those killed by heating lyophilized Mycobacterium tuberculoses (Calbiochem-Perrigen-C) in mineral oil. One group of 10 rats (TB control) was subjected only to this treatment. Another group of 3 rats was not treated at all (normal control). Each test compound was suspended in carboxymeth cellulose (1%) and administered orally to rats (groups of 5 rats) in daily doses of 50 mg / kg, starting on the first day and on the 28th day after the injection of the excipient (29 doses) . The volume of the legs 0 was measured using a Stath-am a pressure sensor and a digital voltmeter using a mercury displacement. Volumes of both injected and non-injected hind legs were measured on day 16, 18, 21, 5 23, 25, 28 and 30. On the 30th day, an X-ray was taken after the animals were sacrificed. The measurements of the volume of the injected paws, carried out from the 16th day to the 30th day, were set aside using a computer for TV-control, normal control and for the animals, the Topi-medication, and the area under the curves (TB-control minus the normal control ) and (animals taking the medication, minus the normal control) were measured. The results are summarized in table. four.
    Table 4
    0
    45
    50
     The% inhibition is the area difference under the curves (GSH) of the average volumes of the non-injected legs laid for day 16, 18, 21, 23, 25, 28 and 30 according to the following formula:
    CPD for treated animals
    % nibi
    PPK TB-control
    It was also shown that the compounds of the formula I prevented ischemia-induced cell damage, in particular neuronal cell damage as a result of the impact, as shown by the following test system.
    Simulation of rat stroke.
    The impact in rats was caused by the causation of four arteries, through which blood is supplied to the brain according to the following procedure. Male Wistar rats were anesthetized with methofan and placed in a sterotoxic tool. A longitudinal incision was made on the dorsal surface of the neck. The neck muscles were retracted by accessing the dorsal surface of the spine. Two vertebral arteries were exposed in the place of their passage through the first spine vertebra. Both arteries were tightly plugged using electric appliances. After the vertebral arteries coagulated, the rat was removed from the stereotoxin instrumentation and the surgical wound was closed. Then on the abdominal surface of the neck did two longitudinal incision. Two normal carotid arteries were exposed and
    Do they remove the surrounding nerves and connect
    wearable fabrics. An atromatic clamp, made mainly of a silicone tube, was applied to each carotid artery so as not to damage and block the vessel. Then surgical wounds were closed. An atromatic clamp is designed so that it can be compressed with a blocked carotid artery if you sweat a small thread of silastic that you walked from the wound. Blood circulation to the brain through the carotid arteries could be restored by relieving the stress of drinking from silastics. After performing surgical operations, they waited 24 hours, the rats did not wake up.
    On the test day, the compounds were suspended in 2% Arabian co-copper and orally administered at different times before induction of shock. Impacts (cerebral ischemia) were caused by compression of the clamps around the carotid arteries for 30 minutes. During this time
    PPK normal control
    X 100
    PPK norm control
    ABOUT
    5 0 5 0
    five
    Q., In
    five
    rats in which the blow was successfully induced lost the right reflex and became insensitive to stimuli. After 30 minutes of ischemia, the load on the clamps was removed with the restoration of blood flow to the brain. The rats were again given the compound in the morning after the stroke. On day 3 after the impact, the animals were given an additional dose of barbiturate anesthetic and their brains were doused in situ with 10% neutral buffer formalin. After washing with formalin in an amount sufficient to fix the brain, the brain was removed and stored in 10% formalin until the preparation of histological sections.
    One of the areas of the brain most susceptible to ischemic damage in both rats and humans is the CA pyramidal cell layer in the hippocampus. In animals that remained insensitive for 30 minutes of ischemia, the CA pyramidal cell layer was completely destroyed. This layer was examined under a microscope in histological sections prepared from the hippocampus. Damage; the brain was graded according to the following scale: O, no damage, completely intact cell layer; 1 - slight damage, one third of the CAj layer is destroyed; 2 - moderate damage, two thirds of the CA layer was destroyed; 3 - severe damage, complete destruction of the CAf layer.
    In order to obtain a ton picture of damage, damage in 10-12 sections from each brain was investigated. The average damage rate was calculated for each tested group. The rates for animals treated with the compounds were compared statistically with those for control groups that received only vehicle (2% gum arabic), which was used to suspend the compounds. The level of significance was determined using Student's t-test. The results are summarized in table. five.
    13
    mg / kg, given orally in 2% gum arabic; the mean value is standard error; three rats showed no damage, one rat died and was revived; p 0.02 + p 0.02; ++ P 0.001.
    Thus, the above examples show that the compounds of the formula I are anti-inflammatory and anti-arthritic agents.
    The following examples of the preparation of compositions can use as an active ingredient any of the compounds of formula I.
    Example 9. Tablets are obtained using the following components.
    Amount mg / tablet
    5- (3,5-ditert. Butyl-4-hydroxyphenyl)
    Metsh1en-4-thiazolidinone250
    Bulkris tallic cellulose400
    Foamy oxide
    silicon 10
    Stearinova
    acid5
    The components are mixed and compressed to form tablets, each weighing 665 mg.
    Example 10. Capsules, each of which contains 150 mg of the drug, are prepared as follows, mg:
    1516012
    14 Table 5
    5- (3,5-di-tert.butyl-4-hydroxyphenyl) methylene-2-thiazolidinone Starch
    Microcrystalline Cellulose Magnesium Stearate
    150 164
    164 22
    Total: 500
    The active ingredient, cellulose, starch, and magnesium stearate are mixed, sieved through a 45 mesh sieve. (U.S. standard) and the resulting mixture fill 500 mg hard gelatin capsules.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining 5- (4-hydroxy-3,5-di-tert-butylphenyl) -methylene thiazolidinone-4 or its derivatives of general formula I
    55
    .
     / J
    where R is hydrogen or C | -C,) is alkyl, characterized in that. 3,5-di-tert-butyl-4-hydroxybenzaldehyde is reacted with the parent at boiling in glacial acetic acid in the presence of an alkali metal acetate, forming the compound of formula II
    ABOUT
    h 15
    is subjected to reduction by trialkyl hydride in the presence of azo-Viso-butyronitrile by boiling in medium
    an inert organic solvent or hydrogen over a palladium catalyst under pressure at 50-120 ° C and the target product of compound I is isolated, where R is hydrogen, or subjected to interaction with sodium hydride and a compound of general formula III
    R - J,
    where R is C, -C-alkyl, while boiling in an inert organic solvent medium to give the desired product of compound I, where R is C-C-alkyl.
    Priority by featured.
    08/09/85 when R is hydrogen;
    02.06.86 when R - C-Cd-alkyl.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1516012A3|1989-10-15|Method of producing 5-|-methylenethiazolidione-4 or its derivatives
    CA1339452C|1997-09-09|Enantiomers of citalopram and derivatives thereof
    Willenborg1979|Experimental allergic encephalomyelitis in the Lewis rat: studies on the mechanism of recovery from disease and acquired resistance to reinduction
    RU2183457C2|2002-06-20|Method for applying 5_ht5-ht1f-antagonist for inhibiting 5_ht5-ht1f-mediated neurogenic meningeal transudation
    CA2065134A1|1992-10-16|Transdermal composition
    AU616907B2|1991-11-14|Melatonin analogues
    Johnson et al.1969|Effect of gastrin on the in vivo incorporation of 14C-leucine into protein of the digestive tract
    Nagasawa et al.1987|. beta.-Substituted cysteines as sequestering agents for ethanol-derived acetaldehyde in vivo
    KR0153443B1|1998-11-16|Aryl-substituted rhodanine derivatives and pharmaceutical formulations thereof
    IE892977L|1990-04-06|Imidazoline derivatives and preparation thereof
    WO1999062892A1|1999-12-09|Aminoazole compounds
    Marshall et al.1981|Tris | aminomethane permits the expression of insulin-induced receptor loss in isolated rat adipocytes
    RU1795965C|1993-02-15|Method of propanolamine derivatives of theirs pharmacologically acceptable acid-additive salts synthesis
    US5661150A|1997-08-26|Drug for neuroprotection
    RU2014329C1|1994-06-15|5-{[3,5-bis-|-4-hydroxyphenyl]- methyl}-4-thiazolidinone showing antiinflammatory and antiarthritis activity
    IE55458B1|1990-09-26|New thieno-pyridinone derivative,process for its preparation,and therapeutic applications thereof
    JP4781362B2|2011-09-28|Quinuclidine compound having a quaternary ammonium group, its preparation method, and use as an acetylcholine blocker
    LaBella1982|Is there an endogenous digitalis?
    JP2001516770A|2001-10-02|Methods of regulating trkA expression
    SU791241A3|1980-12-23|Method of preparing 4,5,6,7-tetrahydroimidazo/4,5c/pyridine derivatives
    EP0100569B1|1986-06-04|Spasmolytically active |s-enantiomer of secoverine
    US4552895A|1985-11-12|Furo[3,2-b]furan-2-|-ones
    Nau et al.1985|Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse
    Kanje1992|Regeneration of an adult peripheral nerve preparation in culture
    Floman1978|Prostaglandin e production by cultured inflamed rat synovium; stimulation by colchicine and inhibition by chloroquine
    同族专利:
    公开号 | 公开日
    CY1619A|1992-07-10|
    IL79648A|1991-12-12|
    IL79648D0|1986-11-30|
    GR862081B|1986-12-24|
    LV10866B|1996-04-20|
    EP0211670A3|1987-05-06|
    PH24517A|1990-07-18|
    DK169324B1|1994-10-10|
    CN1014891B|1991-11-27|
    IE58718B1|1993-11-03|
    KR870000889B1|1987-05-02|
    PT83152B|1989-03-30|
    CA1285572C|1991-07-02|
    JPS6242977A|1987-02-24|
    AU6097286A|1987-02-12|
    EP0211670A2|1987-02-25|
    CN86105036A|1987-02-04|
    AR243173A1|1993-07-30|
    PT83152A|1986-09-01|
    AU590312B2|1989-11-02|
    HK94791A|1991-11-29|
    KR870002109A|1987-03-30|
    ES2001075A6|1988-04-16|
    HUT42765A|1987-08-28|
    NZ217126A|1989-01-27|
    SG80391G|1991-11-15|
    DK376986A|1987-02-10|
    MY102365A|1992-06-17|
    JPH0625182B2|1994-04-06|
    MX9203108A|1992-07-01|
    LV10866A|1995-10-20|
    HU196192B|1988-10-28|
    EP0211670B1|1990-05-09|
    DK376986D0|1986-08-07|
    DE3670951D1|1990-06-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE1038050B|1955-11-17|1958-09-04|Farmaceutici Italia S A Soc|Process for the preparation of 5- derivatives of heterocyclic compounds|
    JPS6310702B2|1980-01-07|1988-03-08|Takeda Chemical Industries Ltd|
    JPS6251955B2|1980-08-22|1987-11-02|Ono Pharmaceutical Co|
    JPS6360015B2|1981-02-05|1988-11-22|
    US4636516A|1981-02-19|1987-01-13|Yamanouchi Pharmaceutical Co., Ltd.|3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds|
    JPS6324498B2|1981-11-09|1988-05-20|Kanegafuchi Chemical Ind|GB8512163D0|1985-05-14|1985-06-19|Fujisawa Pharmaceutical Co|Oxothiazolidine compound|
    US5356917A|1985-08-09|1994-10-18|Eli Lilly And Company|Aryl-substituted rhodanine derivatives|
    US5691367A|1985-08-09|1997-11-25|Eli Lilly And Company|Aryl-substituted rhodanine derivatives|
    US4897406A|1987-11-13|1990-01-30|Nisshin Flour Milling Co., Ltd.|Rhodanine derivatives and pharmaceutical compositions|
    US5208250A|1988-05-25|1993-05-04|Warner-Lambert Company|Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents|
    US5306822A|1988-05-25|1994-04-26|Warner-Lambert Company|Arylmethylenyl derivatives of oxazolidinone|
    IE62214B1|1988-05-25|1995-01-11|Warner Lambert Co|Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents|
    NZ231534A|1988-11-29|1992-02-25|Warner Lambert Co|3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions|
    AT139531T|1989-04-07|1996-07-15|Lilly Co Eli|ARYL-SUBSTITUTED RHODANE DERIVATIVES|
    IL108962A|1989-12-21|1996-12-05|Lilly Co Eli|Use of hydroxybenzyl substituted sulfur containing heterocyclic derivatives a process for their preparation and pharmaceutical compositions containing them|
    US5216002A|1989-12-21|1993-06-01|Eli Lilly And Company|Method of treating inflammatory bowel disease|
    US5143928A|1990-03-27|1992-09-01|Warner-Lambert Company|3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents|
    WO1991017151A1|1990-04-27|1991-11-14|Orion-Yhtymä Oy|New pharmacologically active catechol derivatives|
    DE69221794T2|1991-01-21|1998-03-19|Shionogi Seiyaku Kk|3-BENZYLIDEN-1-CARBAMOYL-2-PYRROLIDONE ANALOG|
    US5158966A|1991-02-22|1992-10-27|The University Of Colorado Foundation, Inc.|Method of treating type i diabetes|
    US5143929A|1991-05-09|1992-09-01|Warner-Lambert Company|2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents|
    IL106877A|1992-09-10|1998-03-10|Lilly Co Eli|Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease|
    EP0595546B1|1992-10-28|1996-03-20|Shionogi & Co., Ltd.|Benzylidene derivatives|
    SK164795A3|1993-06-23|1996-10-01|Chugai Pharmaceutical Co Ltd|Benzene derivatives|
    US6251928B1|1994-03-16|2001-06-26|Eli Lilly And Company|Treatment of alzheimer's disease employing inhibitors of cathepsin D|
    US5476865A|1994-07-06|1995-12-19|Eli Lilly And Company|Methods of inhibiting bone loss|
    HU9702293A3|1995-01-23|2000-08-28|Lilly Co Eli|4-thiazolidinone, rhodanine and 1,3-oxathiolan-5-one derivatives for the preparation of pharmaceutical compositions suitable for the treatment of multiple sclerosis|
    US6005142A|1996-09-03|1999-12-21|Eli Lilly And Company|Process for preparing benzyl-substituted rhodanine derivatives|
    SI0761657T1|1995-09-07|2000-10-31|Eli Lilly And Company|Process for preparing benzyl-substituted rhodanine derivatives|
    US6063799A|1996-09-03|2000-05-16|Eli Lilly And Company|Alternate crystal form of Tazofelone|
    DK0914122T3|1996-07-11|2003-12-22|Warner Lambert Co|Method of Treating and Preventing Neurodegenerative Diseases by Administration of a Thiazolidinone|
    AU6330999A|1998-09-30|2000-04-17|Roche Diagnostics Gmbh|Rhodanine derivatives for the treatment and prevention of metabolic bone disorders|
    AU2002953533A0|2002-12-24|2003-01-16|Arthron Limited|Fc receptor modulating compounds and compositions|
    DE202006018406U1|2006-12-05|2008-04-10|Seda S.P.A.|packaging|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US76416085A| true| 1985-08-09|1985-08-09|
    US86948886A| true| 1986-06-02|1986-06-02|
    [返回顶部]